Professional
Added to YB: 2024-02-22
Pitch date: 2024-02-21
ALNY [bullish]
Alnylam Pharmaceuticals, Inc.
+119.7%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.
Market Cap
$41.7B
Pitch Price
$154.47
Price Target
199.00 (-41%)
Dividend
N/A
EV/EBITDA
66.11
P/E
134.94
EV/Sales
11.24
Sector
Biotechnology
Category
growth
Show full summary:
Alnylam Pharmaceuticals, Inc.: Robust Uptake of Amvuttra Drives Sales; Shares Undervalued
$ALNY 39% sales growth to $1.2B driven by Amvuttra ATTR drug. $199 FVE, undervalued. Maintains leadership vs $IONS Wainua. Diverse pipeline: Onpattro Givlaari Oxlumo vutrisiran HELIOS-B mid-24. RNAi platform edge $3.7B 2032 sales. Profitable 2025.
Read full article (11 min)